All In Biotech

Drug Trial Radar · NCT06756126

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

A Multicenter, Open Label Phase II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AK120 in Adolescents With Moderate-to-severe AD

Last checked: Nov 19, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • AK120Drug

    AK120 subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events(AE)Time frame: week -4 to week 16

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The University of Hong Kong - Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Hunan Pediatric Medical Union

    Changsha, Hunan, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • Ning Bo No.2 Hospital

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.